307 related articles for article (PubMed ID: 23404247)
41. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
42. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
[TBL] [Abstract][Full Text] [Related]
43. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
44. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
[TBL] [Abstract][Full Text] [Related]
45. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
46. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.
Ålgars A; Avoranta T; Österlund P; Lintunen M; Sundström J; Jokilehto T; Ristimäki A; Ristamäki R; Carpén O
PLoS One; 2014; 9(6):e99590. PubMed ID: 24940619
[TBL] [Abstract][Full Text] [Related]
47. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
48. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.
Chang DZ; Kumar V; Ma Y; Li K; Kopetz S
J Hematol Oncol; 2009 Apr; 2():18. PubMed ID: 19386128
[TBL] [Abstract][Full Text] [Related]
49. HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.
Takegawa N; Yonesaka K; Sakai K; Ueda H; Watanabe S; Nonagase Y; Okuno T; Takeda M; Maenishi O; Tsurutani J; Satoh T; Okamoto I; Nishio K; Tamura T; Nakagawa K
Oncotarget; 2016 Jan; 7(3):3453-60. PubMed ID: 26657506
[TBL] [Abstract][Full Text] [Related]
50. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
Ye H; Liu Y; Wu K; Luo H; Cui L
Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
[TBL] [Abstract][Full Text] [Related]
51. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
Kim S; Kim N; Kang K; Kim W; Won J; Cho J
Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
[TBL] [Abstract][Full Text] [Related]
52. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
van Krieken JH; Jung A; Kirchner T; Carneiro F; Seruca R; Bosman FT; Quirke P; Fléjou JF; Plato Hansen T; de Hertogh G; Jares P; Langner C; Hoefler G; Ligtenberg M; Tiniakos D; Tejpar S; Bevilacqua G; Ensari A
Virchows Arch; 2008 Nov; 453(5):417-31. PubMed ID: 18802721
[TBL] [Abstract][Full Text] [Related]
53. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.
Knickelbein K; Tong J; Chen D; Wang YJ; Misale S; Bardelli A; Yu J; Zhang L
Oncogene; 2018 Aug; 37(33):4599-4610. PubMed ID: 29755130
[TBL] [Abstract][Full Text] [Related]
54. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Dienstmann R; Salazar R; Tabernero J
Am Soc Clin Oncol Educ Book; 2015; ():e149-56. PubMed ID: 25993166
[TBL] [Abstract][Full Text] [Related]
55. KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies.
Wen Q; Dunne PD; O'Reilly PG; Li G; Bjourson AJ; McArt DG; Hamilton PW; Zhang SD
Oncotarget; 2017 Jan; 8(2):3206-3225. PubMed ID: 27965461
[TBL] [Abstract][Full Text] [Related]
56. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
[TBL] [Abstract][Full Text] [Related]
57. EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.
Roda D; Castillo J; Telechea-Fernández M; Gil A; López-Rodas G; Franco L; González-Rodríguez P; Roselló S; Pérez-Fidalgo JA; García-Trevijano ER; Cervantes A; Zaragozá R
PLoS One; 2015; 10(6):e0130543. PubMed ID: 26110767
[TBL] [Abstract][Full Text] [Related]
58. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
[TBL] [Abstract][Full Text] [Related]
59. COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.
Zhang Z; Fang C; Wang Y; Zhang J; Yu J; Zhang Y; Wang X; Zhong J
Int J Oncol; 2018 Nov; 53(5):1869-1880. PubMed ID: 30132520
[TBL] [Abstract][Full Text] [Related]
60. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
Tsunoda T; Ishikura S; Doi K; Iwaihara Y; Hidesima H; Luo H; Hirose Y; Shirasawa S
Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
